After Hours Gainer
PVLA Palvella Therapeutics87.84+2.18+2.5%
After Hours:93.00+5.16 (+5.9%)
Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN 3.9% Rapamycin Anhydrous Gel (QTORIN rapamycin) in Microcystic Lymphatic Malformations
Globe NewswireMon, 23-Feb 5:00 PM
